

## Supplemental Online Content

Hansen C, Perofsky A, Burstein R, et al. Trends in Risk Factors and Symptoms Associated With SARS-CoV-2 and Rhinovirus Test Positivity in King County, Washington, June 2020 to July 2022. *JAMA Netw Open*. 2022;5(12):e2245861. doi:10.1001/jamanetworkopen.2022.45861

### eMethods.

**eFigure 1.** Samples Collected Over Time

**eTable 1.** Comparison of Participants Who Enrolled in SCAN Multiple Times vs Participants Who Enrolled Only Once

**eTable 2.** Comparison of the Odds Ratios and Selected Variables Under Different Regression Approaches

**eFigure 2.** Associations Between Demographic Variables

**eFigure 3.** Correlation Matrix for Categorical Variables Using Cramer's V

**eFigure 4.** Sensitivity Analysis for Risk Factors and Symptoms Associated With SARS-CoV-2 Positivity Using Pan-Negative Control Participants and Excluding Asymptomatic Participants

**eFigure 5.** Symptoms Associated With Rhinovirus and SARS-CoV-2 Positivity

**eFigure 6.** Sensitivity Analysis for Risk Factors and Symptoms Associated With Rhinovirus Positivity Using Pan-Negative Control Participants and Excluding Asymptomatic Participants

**eTable 3.** Unadjusted Odds Ratios for SARS-CoV-2 and Rhinovirus Test Positivity

**eTable 4.** Adjusted Odds Ratios for SARS-CoV-2 Test Positivity by Time Period for Variables With Significant Interactions With Time Period

**eFigure 7.** Adjusted Odds Ratios for Rhinovirus Test Positivity for Each Time Period for Variables With Significant Interactions With Time Period

**eFigure 8.** Cross-Correlation Between Rhinovirus and SARS-CoV-2 Test Positivity in the SCAN Study

### eReferences.

This supplemental material has been provided by the authors to give readers additional information about their work.

## eMethods

Here we provide a more detailed description of our methodology including the study design, laboratory methods, variable definitions, and various sensitivity analyses.

### A) Study Design

The Greater Seattle Coronavirus Assessment Network (SCAN) was launched in partnership with Public Health Seattle and King County (PHSKC) on March 23, 2020, to monitor circulation of SARS-CoV-2 in the community. The study was briefly paused on May 12, 2020, for Food and Drug Administration regulatory review and relaunched on June 10, 2020. Here we used data available from June 10, 2020, through July 27, 2022.

SCAN used multiple avenues to recruit participants from the King County area including social media advertising and community outreach through partner organizations. Eligibility criteria changed slightly over the course of the study in response to testing demand and were based on Public Use Microdata Area (PUMA) and reported symptoms (new or worsening fever, cough, or shortness of breath within the past seven days). Each PUMA had a daily allocation of enrollments with over sampling in the less-affluent Southern part of King County to ensure access and equity to testing across the county population. After an initial online screening questionnaire, participants deemed eligible based on residence and presence of symptoms at the time of screening were prompted to complete a detailed demographic and health behavior questionnaire. Enrolled participants received a free PCR-based testing kit delivered to their home for self-collection of a nasal swab.

Beginning in June of 2020, the study accommodated daily enrollments of up to 160 per day. Enrollments peaked at 250 per day between July 4, 2020, and November 17, 2020, at which time enrollments were gradually reduced to 100 per day with a PUMA allocation of 50:50 percent ratio between North and South King County. On January 26, 2021, enrollments were adjusted to 50 online

community enrollments per day and the daily PUMA allocation was set at a 40:60 percent ratio between North and South King County.

SCAN participants were predominantly symptomatic (>90%), although symptoms quotas changed over time to accommodate testing needs. Symptomatic enrollees were defined as SCAN participants who self-reported experiencing either a new or worsening fever, cough, or shortness of breath within the past seven days. Asymptomatic enrollees were defined as individuals self-reporting none of these symptoms. A 75:25 percent ratio of symptomatic: asymptomatic participants was used until June 23, 2020. From June 24, 2020, through December 27, 2021, the ratio of symptomatic to asymptomatic enrollments was adjusted to 95:5 to accommodate the high demand for testing when testing options were limited. On December 28, 2021, the enrollment criteria eliminated the asymptomatic option completely as a direct result of the increased testing demand in response to the Omicron wave. Overall, 92.32% of participants in the Study were categorized as symptomatic enrollments.

In addition to online community enrollments, some participants were invited to participate as part of PHSKC's contact tracing efforts and collaborations with community-based organizations, however these samples were excluded from the analysis. We also excluded participants residing outside of King County and those reporting a positive SARS-CoV-2 test within the last 90 days, to avoid catching the later parts of long-lasting SARS-CoV-2 episodes, which would make it difficult to identify risk factors of the early infection process. Exclusion criteria and sample size is shown in the main text (Figure 1). To maintain independence between observations, each participant was included in analysis only once. For participants enrolling more than once, we used the first positive SARS-CoV-2 or rhinovirus test or most recent negative SARS-CoV-2 test, after excluding observations with missing data. Few participants tested positive for SARS-CoV-2 through SCAN more than once with an interval greater than 90 days, and of participants who enrolled multiple times, more than 90% tested negative for SARS-CoV-2 at every

enrollment. Using the most recent negative test increased the sample size in the later periods of the study when daily quotas were lowered and enrollment declined. eTable 2 compares participants who enrolled multiple times to participants who enrolled only once.

### B) Variable Definitions

Five core sociodemographic variables were included in all models, including 3 individual-level variables: age (<12 years, 12-50 years, ≥50 years), sex (female, male), race/ethnicity (Asian (non-Hispanic), Black (non-Hispanic), Hispanic (any race), White (non-Hispanic), Other (includes American Indian or Alaska Native, Native Hawaiian and other Pacific Islander, other, and two or more races); and 2 geographic variables addressing local risk in the community: region of the county (North, South), and social and economic risk index (SERI). SERI was developed by PHSKC, using a combination of variables from the 2015-2019 American Community Survey, as a geographic indicator to describe socioeconomic inequalities and identify communities at increased risk of COVID-19.<sup>1</sup> With SERI, census tracts are given a score by summing the values from eight unweighted variables including: 1) the percentage of the population identifying as people of color; 2) the percentage of limited English-speaking households; 3) the percentage of the population born outside of the United States; 4) the median number of occupants per household; 5) the percentage of adults in essential healthcare-related occupations; 6) the percentage of adults in essential non-healthcare occupations; 7) the percentage of adults age 25+ with less than a college degree; and 8) the percentage of households earning less than 200% of the federal poverty level. These scores are standardized to a range between 0 and 1 and divided into three risk levels: low, moderate, or high. For each participant, a SERI category was assigned based on the reported census tract of residence.

Additional independent variables analyzed included recent contact with a SARS-CoV-2 case (confirmed, suspected, none), vaccination status of the contact (added in October 2021: vaccinated, not vaccinated, don't know), symptom status of the contact (added October 2021: symptomatic,

asymptomatic, don't know), vaccination status of the participant (Added in January 2021: not fully , fully; Added in October 2021: boosted), household size (<5 persons per household, ≥5 persons), housing type (house , apartment, other), work location (home, home and onsite, onsite, not employed), recent history of international or domestic travel (yes, no), care seeking for current illness (yes, no), self-reported prior test history (no prior positive test , prior positive <90 days ago (excluded), prior positive >90 days ago, never tested). We also collected careful data on symptoms experienced in the last 7 days based on 16 indicator variables (loss of smell or taste, fever, cough, chills/shivering, headaches, ear pain/discharge, runny/stuffy nose, sore throat, muscle/body aches, fatigue, sweats, diarrhea, increased trouble breathing, nausea/vomiting, rash, and eye pain), and an indicator for experiencing more than three symptoms.

We categorized participants based on the number of vaccine doses and time since last vaccination. Participants were considered fully vaccinated 14 days after their second dose of an mRNA vaccine or a single dose of the Johnson & Johnson vaccine. Individuals were considered boosted 14 days after they received an additional mRNA vaccine following their primary vaccine series. Few participants remained unvaccinated in King County in the period where we were interested in vaccine effects, particularly during the Delta and Omicron waves. Therefore, participants who did not complete their primary schedule, or remained unvaccinated, were pooled into the “not fully vaccinated” category. We also categorized participants who completed a primary series without a booster dose based on whether their last vaccination dose was less or more than 6 months prior to study enrollment. Following standard practice, we defined vaccine effectiveness as 1-odds ratio x 100.

We used a categorical variable for time-period: wild-type variant (June 10, 2020-January 31,2021), pre-Omicron variants (February 1, 2021 – December 11, 2021), omicron variants (December 12, 2021-July 27,2022). The wild-type variant period represents the period before variant circulation and vaccination. Vaccination started for adults ≥65 years in King County in December 2020 but was not

common among our study participants until after January 2021 (main text, Figure 2b). The pre-Omicron variants period represents the circulation of multiple variants (with Delta becoming dominant in summer/fall 2021) and the ramp up of vaccination. The Omicron variants period is characterized by widespread vaccination and dominance of Omicron variants. We chose not to divide the pre-Omicron variants period into multiple variant-specific periods out of concern for sample size and because several variants co-circulated in King County during spring and summer 2021.<sup>2</sup> We obtain Delta specific estimates through a separate regression model. We also explored including the Oxford Stringency Index<sup>3</sup> for Washington State, a composite score of non-pharmaceutical interventions ranging from 0-100, as a continuous variable in our model, but this was dropped during variable selection.

### C) Laboratory Methods

Laboratory methods have been described elsewhere.<sup>4,5</sup> Participants received self-swabbing kits at home within 24 hours of requesting a test via a special carrier.<sup>6</sup> After swabbing, participants shipped their self-collected swabs to the Brotman Baty Institute for Precision Medicine, Seattle, Washington for laboratory testing within 48-72 hours of swabbing and 10 days of symptoms onset. Samples were tested on a Clinical Laboratory Improvement Amendments-compliant laboratory designed PCR test for the presence of SARS-CoV-2 on 2 multiplex assays (total of 4 RT-PCR reactions) targeting the Orf1b and S genes. A positive SARS-CoV-2 result had Ct values <40 on 3 of the 4 targets.

We assigned the putative variant in each swab based on the response to the S-gene. A sample was deemed “S-gene Target Failure” (SGTF) if the mean Ct for the Orf1b target was <30 and the difference between the mean Orf1b Ct and the mean S-gene Ct was ≥6 or the mean Ct for the Orf1b target was <30 and the Ct values for the S-gene targets were undetermined. A sample was deemed S-gene Target Return (SGTR) if the mean Ct for the Orf1b targets was <33, and the difference between the mean Orf1b Ct and the mean S-gene Ct was ≤3 (no undetermined Ct values). SGFT specimens collected during June-

December 2021 were presumed Delta, while SGTR specimens collected after November 1, 2021, were deemed Omicron.

A majority of samples (83.95%) was also tested for 24 other respiratory pathogens (eFigure 1), by TaqMan RT-PCT on the OpenArray platform (Thermo Fisher). The OpenArray platform includes primers for two clades of rhinovirus (2 RT-PCR reactions per primer). The rhinovirus primers on the OpenArray platform detect both rhinovirus and enterovirus. Additionally, there is a separate primer for enterovirus alone. For a positive rhinovirus result, both Crt values for at least one rhinovirus primer set must be <28, with an Amp Score >1.0, and a CQ Confidence >0.5. Samples with a positive enterovirus result, in addition to a positive rhinovirus, were considered positive for enterovirus and were excluded from the analysis because we could not rule out the possibility of coinfections with rhinovirus.

#### **D) Exploring interactions with time-period**

To explore changes in risk factors over time, we tested interactions one at a time between each variable in the adjusted model (after variable selection) and time-period, with the wild-type variant period as the reference. We used a significance threshold of 0.001 (adjusting for multiple comparisons, 0.05/31 variables tested). Interactions meeting this criterion were included in the model together and were retained if they remained significant at  $p<0.05$ . Both region and SERI showed evidence of interaction with time. Because region and SERI were closely correlated (eFigure 3), we only included an interaction with region in the final model as it had a smaller p-value and fewer levels, resulting in a simpler model. We were not able to test the interaction between time-period and vaccination status as no participants were fully vaccinated during the reference time-period. Confidence intervals were based on non-parametric bootstrap (1000 simulations). To assess model fit we used McFadden's pseudo  $R^2$ , where values between 0.2-0.4 are considered to signify good model fit. Our final model had a value of 0.34.

To examine characteristics associated with presumed Delta and Omicron cases, we included the five core demographic variables, any variable with a significant interaction with time-period, any variable that was significant ( $p<0.05$ ) in the final model with an odds ratio  $>2$ , and any non-symptom variable that had a significantly protective effect ( $p<0.05$ ).

**E) Sensitivity analyses using different regression approaches:**

In the main analysis, we used multivariable logistic regression with AIC selection to assess risk factors for SARS-CoV-2 and rhinovirus test-positivity. In sensitivity analyses, we also considered two complementary approaches for variable selection: LASSO regression using the `glmnet` package<sup>7</sup> and Bayesian Model Averaging using the `BMA` package.<sup>8</sup> The results of the three approaches are compared in eTable 2. For our LASSO regression model, we selected the optimal regularization parameter (`lambda`) through 10-fold cross-validation, and we report covariates retained by the model when using `lambda.min` (the `lambda` of the minimum mean cross-validated error) and `lambda.1se` (the largest value of `lambda` such that the error is within 1 standard error of the minimum mean error). We found that the LASSO regression model using `lambda.1se` (i.e., the most regularized model) retained the fewest variables, with coefficients for retained variables closer to 0 (1 after exponentiation) than the other models. This is expected as the LASSO model is based on coefficient shrinkage and has the strongest stringency for variable inclusion; yet the variables retained by LASSO and their coefficients were consistent with those of the key risk factors identified in stepwise logistic regression. Bayesian Model Averaging also retained fewer variables than stepwise regression, and similarly, coefficients for the retained variables were consistent between the two methods.

#### **F) Sensitivity Analysis Using Different Control Groups**

For both SARS-CoV-2 and rhinovirus, we conducted sensitivity analyses that excluded any cases with coinfections and restricted the controls to participants tested for 24 additional pathogens and negative for all (pan-negative). The rationale being that participants who were negative for SARS-CoV-2 or rhinovirus but positive for other pathogens may share risk factors and including them in the control group may dilute the estimated odds ratios. To further standardize our sample and account for changes in the proportion of asymptomatic participants, we ran additional sensitivity analyses that restricted the sample to participants reporting at least one symptom. Results from these sensitivity analyses were broadly similar to the main analysis and are provided in eFigure 4 and eFigure 5. Additionally, we ran a sensitivity analysis stratifying by region (North and South), and again results were broadly similar.

#### **G) Sensitivity Analysis Using Weekly Incidence Instead of Time-Period for Interactions**

To explore if the interaction between contact with a SARS-CoV-2 case and time-period was a function of increased circulation in the community, resulting in a greater likelihood of unknown contacts, we tested the interaction between contact with a case and our external measure of community incidence (the log of the weekly cases reported in the community). We found a significant interaction ( $p<0.0001$ ) indicating that for each unit increase in community incidence the odds ratio associated with contact with a case decreased by 56%. To disentangle the correlation between community incidence and the Omicron variant, we also tested the interaction between community incidence and loss of smell and taste. This interaction was not statistically significant. This suggests that the changes we see in symptom presentation are driven by differences in variants rather than high levels of circulation.

## H) SCAN Study Questionnaire

The Study questionnaire was updated several times throughout the study to reflect changes in behavioral recommendations and interventions such as hygiene and vaccination. The version of the questionnaire provided here is the most recent version of the survey, reflecting changes made on October 5, 2021. We only included variables in the model if they were consistently asked throughout the study period and were missing <5% of data.

# Illness Questionnaire

---

Record ID \_\_\_\_\_

---

Hello [participant\_first\_name]!

Please complete this three-part survey.

Part 1: Questionnaire Part 2: Activate your SCAN Kit Part 3: Nasal Swab Collection A link to Part 2 and Part 3 of the survey will be emailed to you once we ship your SCAN Kit. You should complete Part 2 and Part 3 when you receive your SCAN Kit in the mail.

---

## Part 1: Questionnaire

---

Why are you participating in SCAN/ having a COVID-19 test today?

- I believe I have been exposed
  - I have symptoms
  - I plan to travel/be near high-risk individuals/attend an event in the next week
  - I have other reasons to get tested
- 

Who are you completing this survey for?

- Myself
  - A member of my household
- 

Have you been sick in the past week with a new fever, new or worsening cough, or new or worsening shortness of breath?

- Yes
  - No
- 

Which new or worsening symptoms have you experienced in the last 7 days? Pick any that answer the question.

- I don't have any symptoms
  - Feeling feverish
  - Headache
  - Cough
  - Chills or shivering
  - Sweats
  - Sore throat or itchy/scratchy throat
  - Nausea or vomiting
  - Runny or stuffy nose
  - Feeling more tired than usual
  - Muscle or body aches
  - Increased trouble with breathing
  - Diarrhea
  - Rash
  - Ear pain or ear discharge
  - Eye pain
  - Loss of smell or taste
- 

When did you first notice your current illness?  
Select the date on the calendar.

\_\_\_\_\_  
(MM-DD-YYYY)

Note: Today's date is highlighted in yellow on the calendar.

---

Today

---

Future dates are not allowed. Please change the date on the calendar to a past date to continue with the survey.

<p>Have you sought clinical care for your current illness since it started? Select all that apply.</p>	<input type="checkbox"/> I haven't sought care or am not currently sick <input type="checkbox"/> Yes, in person at a Doctor's Office or Urgent Care <input type="checkbox"/> Yes, in person at a Pharmacy (Drugstore) <input type="checkbox"/> Yes, in person at a Hospital or Emergency Department <input type="checkbox"/> Yes, via phone or internet <input type="checkbox"/> Yes, Other
<hr/>	
<p>Have you ever been tested for COVID-19?</p>	<input type="radio"/> Yes <input type="radio"/> No
<hr/>	
<p>Have you ever tested positive for COVID-19?</p>	<input type="checkbox"/> Yes, I tested positive with a nose, mouth, or throat swab <input type="checkbox"/> Yes, I tested positive for antibodies with a blood sample <input type="checkbox"/> No <input type="checkbox"/> I don't know (Select all that apply.)
<hr/>	
<p>What was the date of your most recent positive COVID-19 swab test?</p>	<small>(If you cannot remember the exact date, please estimate.)</small>
<hr/>	
<p>What type of COVID-19 test(s) have you had?</p>	<input type="checkbox"/> Nose swab through the SCAN Study or Seattle Flu Study <input type="checkbox"/> Nose, mouth, or throat swab from a clinic, hospital, workplace, or other <input type="checkbox"/> Antibody test from a blood sample <input type="checkbox"/> Other (Select all that apply.)
<hr/>	
<p>About how many times have you been tested for COVID-19?</p>	
<hr/>	
<p>What was the result of your most recent test?</p>	<input type="radio"/> Positive <input type="radio"/> Inconclusive <input type="radio"/> Negative <input type="radio"/> I don't know
<hr/>	
<p>In the past 2 weeks, have you been in close contact with someone who tested positive for COVID-19? Close contact means that you were less than 6 feet away for at least 10 minutes.</p>	<input type="checkbox"/> No, I have not been in close contact with anyone that tested positive for COVID-19 <input type="checkbox"/> Yes, a member of my household tested positive <input type="checkbox"/> Yes, I have been in close contact with a co-worker that tested positive <input type="checkbox"/> Yes, I have been in close contact with a friend or person I know that tested positive <input type="checkbox"/> Maybe, I was in close contact with someone with COVID-19 symptoms, but I don't know if that person has been tested <input type="checkbox"/> Maybe, I was in close contact with someone with COVID-19 symptoms and was tested, but I don't yet know the test result <input type="checkbox"/> I don't know <input type="checkbox"/> Prefer not to say (Select all that apply.)

---

If you have been in contact with someone who tested positive for COVID-19 in the past 2 weeks, was that person symptomatic at the time?	<input type="radio"/> Yes <input type="radio"/> No <input type="radio"/> I don't know <input type="radio"/> Prefer not to say
If you have been in contact with someone who tested positive for COVID-19 in the past 2 weeks, was that person vaccinated for COVID-19?	<input type="radio"/> Yes <input type="radio"/> No <input type="radio"/> I don't know <input type="radio"/> Prefer not to say
Have you been in contact with anyone experiencing respiratory symptoms who tested negative for COVID-19?	<input type="radio"/> Yes <input type="radio"/> No <input type="radio"/> I don't know <input type="radio"/> Prefer not to say
In the past 14 days, have you attended any community event or social gathering, such as a party, wedding, funeral, sporting event, festival, rally, or performance venue?	<input type="radio"/> Yes, with 1-2 others who do not live with me <input type="radio"/> Yes, with 3-5 others who do not live with me <input type="radio"/> Yes, with 6-10 others who do not live with me <input type="radio"/> Yes, with 11-20 others who do not live with me <input type="radio"/> Yes, with more than 20 others who do not live with me <input type="radio"/> No <input type="radio"/> I don't know <input type="radio"/> Prefer not to say
Think back to the last time you socialized with friends or family you don't live with. Which precautions did you take? Select all that apply.	<input type="checkbox"/> I wore a facemask <input type="checkbox"/> I stayed outdoors <input type="checkbox"/> I ventilated indoor spaces (opened windows/doors, used fans) <input type="checkbox"/> I did not share food or drinks with others <input type="checkbox"/> I quarantined for 14 days before the social event <input type="checkbox"/> I got tested for COVID-19 1-3 days before the social event <input type="checkbox"/> I stayed 6 feet apart from others <input type="checkbox"/> I washed my hands with soap or used hand sanitizer before, during, and after the social event <input type="checkbox"/> I cleaned and disinfected frequently touched items and surfaces <input type="checkbox"/> I only socialize with individuals who are fully vaccinated <input type="checkbox"/> None of the above <input type="checkbox"/> Prefer not to say
Do you use any of the following products (either indoors or outdoors)?	<input type="checkbox"/> Tobacco products (e.g. cigarettes, cigars, pipes) <input type="checkbox"/> Electronic cigarettes/vapor pens <input type="checkbox"/> Prefer not to say <input type="checkbox"/> None of the above (Select all that apply.)

---

---

Do you have any of the following underlying medical conditions? Select all that apply

- Cancer
  - Chronic kidney disease
  - COPD (chronic obstructive pulmonary disease)
  - Down Syndrome
  - Heart conditions, such as heart failure, coronary artery disease, or cardiomyopathies
  - Immunocompromised state from solid organ transplant
  - Immunocompromised state from blood or bone marrow transplant, immune deficiencies, HIV, use of corticosteroids, or other immune-weakening medications
  - overweight or obese (body mass index [BMI] of 25kg/m<sup>2</sup> or higher)
  - Sickle Cell Disease
  - Type 1 diabetes mellitus
  - Type 2 diabetes mellitus
  - Moderate-to-severe asthma
  - Cerebrovascular disease (affects blood vessels and blood supply to the brain)
  - Cystic fibrosis
  - Hypertension or high blood pressure
  - Neurologic conditions, such as dementia
  - Liver disease
  - Pulmonary fibrosis (having damaged or scarred lung tissues)
  - Thalassemia (a type of blood disorder)
  - None of the above
  - Prefer not to say
  - I don't know
- 

Have you received this season's influenza (flu) vaccine (since July 1, 2021)? This includes both flu mist nasal spray and the flu shot.

- Yes
  - No
  - Do not know
- 

If completing for a child < 8 years old, did the child receive 2 doses of the influenza vaccine?

- Yes
  - No
  - I don't know
  - Prefer not to say
  - Not applicable
- 

If you are 65 or older, did you receive the high-dose influenza vaccine?

- Yes
  - No
  - I don't know
  - Prefer not to say
  - Not applicable
- 

How did you receive the flu vaccine this season (since July 1, 2021)?

- Injection (flu shot)
- Nasal spray (flu mist)

---

What month did you get the flu shot or flu mist nasal spray this season (since July 1, 2021)?

July 2021  
 August 2021  
 September 2021  
 October 2021  
 November 2021  
 December 2021  
 January 2022  
 February 2022  
 March 2022  
 April 2022  
 May 2022  
 June 2022  
 Do not know

---

Did you receive the flu vaccine last season?  
(July 1, 2020 - July 1, 2021)

Yes  
 No  
 I don't know  
 Prefer not to say

---

Has anyone in your household not received this year's influenza vaccine (since July 1, 2021)?

Yes  
 No  
 I don't know  
 Prefer not to say

---

Have you received a COVID-19 vaccine since December 1, 2020?

Yes  
 No  
 I don't know  
 Prefer not to say

---

How many doses (shots) of the COVID-19 vaccine did you receive?

1 shot  
 2 shots  
 3 shots  
 I do not know  
 Prefer not to say

---

What is the manufacturer's name of the first dose of the COVID-19 vaccine that you received?

Pfizer  
 Moderna  
 Novavax  
 Johnson & Johnson / Janssen  
 AstraZeneca  
 Other  
 I don't know  
 Prefer not to say

---

Please specify:

---

When did you receive your first dose of the COVID-19 vaccine? If you do not know the exact date, please estimate.

---

What is the manufacturer's name of the second dose of the COVID-19 vaccine that you received?

Pfizer  
 Moderna  
 Novavax  
 Johnson & Johnson / Janssen  
 AstraZeneca  
 Other  
 I don't know  
 Prefer not to say

Please specify:

---

When did you receive your second dose of the COVID-19 vaccine? If you do not know the exact date, please estimate.

---

What is the manufacturer's name of the third dose of the COVID-19 vaccine that you received?

- Pfizer
  - Moderna
  - Novavax
  - Johnson & Johnson / Janssen
  - AstraZeneca
  - Other
  - I don't know
  - Prefer not to say
- 

Please specify:

---

When did you receive your third dose of the COVID-19 vaccine? If you do not know the exact date, please estimate.

---

Is anyone in your household not vaccinated for COVID-19?

- Yes
  - No
  - I don't know
  - Prefer not to say
- 

In the past 2 weeks, have you been able to work from home?

- I am not currently employed
  - No, I always have to be on-site for work
  - Yes, I have only worked from home
  - I have worked both from home AND on-site
  - Prefer not to say
- 

What industry best describes your work?

- Grocery store
  - Pharmacy
  - Restaurant/bar
  - Non-grocery retail store
  - Warehouse/shipping center
  - Government/public service
  - Delivery driver (food)
  - Delivery driver (parcel or package)
  - Public transportation/airline/airport
  - School or childcare
  - Long-term care facility
  - Healthcare setting
  - Assisted living facility
  - Other
  - Prefer not to say
- (Select all that apply.)
- 

What other industry best describes your work?

---

In the last 14 days, have you worked/volunteered in, or otherwise visited any of the following locations?  
Select all choices that are true for you.

- Restaurant/cafe
- Bar/music venue
- Gym/exercise facility
- Salon/barber shop
- Grocery store
- Other (non-grocery) shopping establishment
- School
- Childcare Facility
- Adult long-term care facility
- Doctor's office, or healthcare facility (excluding long-term care)
- Essential workplace (excluding healthcare)
- Other workplace
- Place of worship
- Public transportation (bus, light rail, train)
- Airport
- None of the above

#### **Recent Travel**

In the past 14 days, have you visited a country other than the US?

- No, I have not traveled outside the US
- Yes

In the past 14 days have you traveled to a US state other than Washington State?

- No, I have not traveled outside Washington State
- Yes

**Demographic Information**

What was your sex at birth?

- Male  
 Female  
 Other (please specify)  
 Prefer not to say

What is your current gender identity?

- Cisgender man  
 Cisgender woman  
 Genderqueer/non-binary  
 Man  
 Transgender man/trans man  
 Transgender woman/trans woman  
 Woman  
 Another gender not listed (please specify)  
 Prefer not to answer

What is your current gender identity? Please specify.

---

What is your sex? Please specify.

---

Are you currently pregnant?

- Yes  
 No  
 Prefer not to say

Are you Hispanic or Latina/Latino/Latinx?

- Yes  
 No  
 Prefer not to say

How would you describe your race?

- American Indian or Alaska Native  
 Asian  
 Native Hawaiian or other Pacific Islander  
 Black or African American  
 White  
 Other  
 Prefer not to say  
(Select all that apply.)

Please choose the range that best represents your household income last year (before taxes). If you are still considered a dependent for tax purposes, choose the range that describes your parent/legal guardian's household income.

- Less than or equal to \$25,000  
 Between \$25,001 to \$50,000  
 Between \$50,001 to \$75,000  
 Between \$75,001 to \$100,000  
 Between \$100,001 to \$125,000  
 Between \$125,001 to \$150,000  
 Over \$150,000  
 Don't know  
 Prefer not to say

---

What is your highest level of education?

Child under 5 years old  
 Currently in elementary school  
 Currently in middle school  
 Some high school or currently in high school  
 Graduated high school/obtained GED  
 Some college (including vocational training, associate's degree)  
 Bachelor's degree  
 Advanced degree (Master's, doctorate, medical degree, or other post-graduate educational degree)  
 Prefer not to say

---

Where do you live?

House/condo/townhouse  
 Homeless Shelter  
 Apartment  
 Dormitory  
 Assisted or senior living facility  
 Skilled nursing center  
 Long term care or rehab facility  
 Adult family home  
 Inpatient or behavioral health residential center  
 Permanent supportive or transitional housing center  
 Correctional facility  
 I don't stay in the same place every night  
 Other

---

Including yourself, how many people share your kitchen or living space?

I live by myself  
 2 people  
 3 people  
 4 people  
 5 people  
 6 or more people

---

Do you have anyone in your household < 5 years old?

Yes  
 No  
 Prefer not to say

---

Do you have anyone in your household 5 to 12 years old?

Yes  
 No  
 Prefer not to say

---

Is there a reason you chose at-home testing through SCAN over other testing services or locations? Select all that apply.

I prefer to get tested from home  
 It's free  
 It's difficult to get an in-person appointment for testing  
 I feel like I'm contributing to scientific research  
 Other: \_\_\_\_\_  
 I prefer not to say

---

Illness Questionnaire Date

---


Illness Questionnaire Date and TIME

---

**REMINDER:** We are going to send a link to activate your SCAN Kit by [text\_or\_email] when you receive it. Please be on the lookout for this [text\_or\_email], as you will need to enter your sample barcode in the survey when you complete your SCAN Kit. Your sample barcode will be on your SCAN Kit box and on your sample tube. Please make sure that you do not mail your SCAN Kit back to us until you have completed the Kit Activation survey, entered in your sample barcode, and written your first and last name on your sample tube. If you do not, we may be unable to test your sample.

### eFigure 1. Samples Collected Over Time

Bars are color coded to represent the number of samples tested for SARS-CoV-2 only and those tested for SARS-CoV-2 and 24 other respiratory pathogens including rhinovirus. From November 3, 2020 – December 31, 2020, only 20% of samples were tested on the OpenArray multipathogen PCR platform for non-SARS-CoV-2 pathogens, due to budget constraints. The study prioritized continuing to provide as many SARS-CoV-2 tests as possible through the end of 2020.



**eTable 1. Comparison of Participants Who Enrolled in SCAN Multiple Times vs Participants Who Enrolled Only Once**

For participants who enrolled multiple times, table data are based on the single observation included in the analysis.


	<b>Single Enrollment (N=17829) N (%)</b>	<b>Multiple Enrollments (N=5449) N (%)</b>
<b>Number of enrollments</b>		
Median (Min, Max)	1.00 (1.0 - 1.0)	2.0 (2.00 - 28.0)
<b>Age</b>		
Median (IQR)	34.25 (21.67 – 45.75)	34.83 (24.25 – 43.46)
<b>Age Group (years)</b>		
12-50	11945 (66.54)	4161 (75.03)
<12	2552 (14.22)	581 (10.48)
≥50	3455 (19.25)	804 (14.50)
<b>Sex</b>		
Female	10430 (58.10)	3448 (62.17)
Male	7522 (41.90)	2098 (37.83)
<b>Race/ethnicity N</b>		
Asian (non-Hispanic)	3001 (16.72)	1017 (18.34)
Black (non-Hispanic)	515 (2.87)	139 (2.51)
Hispanic (any race)	1747 (9.73)	446 (8.04)
White (non-Hispanic)	11124 (61.97)	3489 (62.91)
Other	1565 (8.72)	455 (8.20)
<b>Region</b>		
North	12424 (69.21)	3695 (66.62)
South	5528 (30.79)	1851 (33.38)
<b>Social &amp; Economic Risk Index</b>		
Low	7096 (39.53)	2073 (37.38)
Moderate	5945 (33.12)	1872 (33.75)
High	4911 (27.36)	1601 (28.87)
<b>Work Location</b>		
Home	5968 (33.24)	1980 (35.70%)
Home & onsite	2118 (11.80)	838 (15.11%)
Onsite	3192 (17.78)	1087 (19.60%)
Not employed	6674 (37.18)	1641 (29.59%)
<b>Attend/work at school</b>		
No	15554 (86.64)	4698 (84.71)
Yes	2398 (13.36)	848 (15.29)

**eTable 2.** Comparison of the Odds Ratios and Selected Variables Under Different Regression Approaches


Variable	All variables	Stepwise AIC	LASSO (lambda min)	LASSO (lambda 1se)	BMA
<12 yrs	1.19		1.15		
50+ yrs	1.16		1.11		
Male	1.07		1.05		
Asian	1.07	1.08	1.04		1.07
Black	2.02	2.00	1.95	1.05	2.26
Hispanic	2.06	2.05	1.99	1.32	2.19
Other Race	1.29	1.29	1.24		1.39
South	1.55	1.56	1.57	1.47	2.03
Moderate	1.16	1.16	1.11		
High	1.48	1.48	1.43	1.19	
5+ ppl	1.39	1.39	1.38	1.03	1.43
Apartment	1.16	1.14	1.13		
Other Housing	1.51	1.49	1.44		
Confirmed Contact	3.89	3.87	3.80	2.97	3.94
Suspected Contact	1.19	1.18	1.15		1.20
Home & Onsite	0.88	0.89	0.89		
Onsite	1.08	1.09	1.06		
Not Employed	1.19	1.25	1.18		
School Attendance	0.64	0.65	0.67		0.68
International Travel	2.29	2.30	2.18		2.26
Domestic Travel	1.55	1.55	1.48		1.45
Chills/Shivering	1.74	1.73	1.72	1.54	1.82
Cough	2.49	2.54	2.46	1.92	2.57
Runny/Stuffy Nose	1.33	1.33	1.29		1.31
Sore Throat	0.85	0.84	0.88		
Muscle/Body Aches	1.49	1.45	1.45	1.12	1.51
Fatigue	0.90		0.93		
Fever	2.37	2.40	2.34	1.91	2.52
Sweats	1.16	1.15	1.14		
Diarrhea	0.64	0.64	0.67		0.66
Trouble Breathing	0.58	0.57	0.60		0.57
Nausea/Vomiting	0.59	0.59	0.61		0.62
Rash	0.43	0.44	0.48		
Loss of Smell/Taste	3.51	3.46	3.41	2.46	3.52
Eye Pain	1.60	1.56	1.53		1.25
Ear Pain/Discharge	0.98				
Headaches	1.01				
3+ Symptoms	1.28	1.22	1.23		
Prior Positive >90days	0.37	0.37	0.40		0.39
No Prior Test	1.19	1.20	1.16		1.25
Fully >6m	0.97	0.93			
Fully <6m	0.67	0.65	0.72		
Boosted	0.75	0.72	0.80		
Care Sought	0.78	0.78	0.82		
Pre-Omicron	1.34	1.37	1.27		1.20
Omicron	3.20	3.25	2.97	2.19	2.57
Incidence	1.59	1.60	1.58	1.41	1.61

**eFigure 2. Associations Between Demographic Variables**

Reading from left to right, the numbers represent the proportion of each level from the top variable (x-axis) within the levels of the variables on the right (y-axis). For example, among children <12 years, .60 (60%) are White, .12 (12%) are Asian, etc. The shading represents the % positive for SARS-CoV-2 in that group. The highest % positive (~30%) is among Black participants living in households with ≥5 people.




**eFigure 3. Correlation Matrix for Categorical Variables Using Cramer's V**




**eFigure 4. Sensitivity Analysis for Risk Factors and Symptoms Associated With SARS-CoV-2 Positivity Using Pan-Negative Control Participants and Excluding Asymptomatic Participants**

The first column displays the odds ratios from the final (core) model (without interactions), ordered from greatest to least. The second column displays the odds ratios when the sample is restricted to pan-negative controls, with all coinfections removed from the cases. The third column displays the odds ratios when the sample is restricted to participants reporting at least one symptom. The last two columns represent separate analyses of the core model for North and South King County participants (more and less affluent populations, respectively).




**eFigure 5.** Symptoms Associated With Rhinovirus and SARS-CoV-2 Positivity



**eFigure 6. Sensitivity Analysis for Risk Factors and Symptoms Associated With Rhinovirus Positivity Using Pan-Negative Control Participants and Excluding Asymptomatic Participants**

The first column displays the odds ratios from the final (core) model (without interactions), ordered from greatest to least. The middle column displays the odds ratios when the sample is restricted to pan-negative controls, with all coinfections removed from the cases. The third column displays the odds ratios when the sample is restricted to participants reporting at least one symptom.



**eTable 3. Unadjusted Odds Ratios for SARS-CoV-2 and Rhinovirus Test Positivity**

Adjusted estimates provided in the main text (Figure 3).

(\*p&lt;0.05; \*\*p&lt;0.001; \*\*\*p&lt;0.0001).

Characteristic	SARS-CoV-2	Rhinovirus
	OR (95% CI)	OR (95% CI)
<b>Age</b>		
12 – 50 years (Ref)	1.0	1.0
<12 years	1.00 ( 0.80- 1.13)	5.13 (4.66-5.65)***
50+ years	1.00 ( 0.85- 1.14)	0.37 (0.31-0.44)***
<b>Sex</b>		
Female (Ref)	1.0	1.0
Male	1.00 ( 0.93- 1.17)	1.07 (0.99-1.17)
<b>Race/ethnicity</b>		
Asian (non-Hispanic)	1.50 ( 1.30- 1.76)***	0.78 (0.69-0.88)**
Black (non-Hispanic)	3.50 ( 2.72- 4.41)***	1.03 (0.79-1.33)
Hispanic (any race)	3.10 ( 2.61- 3.56)***	1.16 (1.01-1.34)*
White (non-Hispanic) (ref)	1.0	1.0
Other Race	1.90 ( 1.57- 2.27)***	1.29 (1.12-1.48)**
<b>Region</b>		
North (Ref)	1.0	1.0
South	3.40 ( 3.06- 3.83)***	1.25 (1.14-1.37)***
<b>SERI</b>		
Low (Ref)	1.0	1.0
Moderate	1.60 ( 1.34- 1.85)***	1.07 (0.97-1.18)
High	3.90 ( 3.42- 4.56)***	1.24 (1.12-1.37)***
<b>Household Size</b>		
<5 people (Ref)	1.0	1.0
≥5 people	1.80 ( 1.61- 2.07)***	1.52 (1.37-1.68)***
<b>Housing Type</b>		
House (Ref)	1.0	1.0
Apartment	1.50 ( 1.30- 1.69)***	0.59 (0.52-0.67)***
Other Housing	2.60 ( 1.76- 3.74)***	0.32 (0.16-0.57)**
<b>Contact with SARS-CoV-2 Case</b>		
No Contact (Ref)	1.0	
Confirmed Contact	7.10 ( 6.27- 7.99)***	
Suspected/Possible Contact	1.70 ( 1.42- 2.08)***	
<b>Work Location</b>		
Home (Ref)	1.0	1.0
Home & Onsite	1.20 ( 0.98- 1.48)	1.06 (0.91-1.24)
Onsite	2.40 ( 2.09- 2.86)***	1.14 (1.00-1.31)*
Not Employed	1.70 ( 1.49- 1.99)***	2.12 (1.92-2.34)***
<b>Binary Variables (Ref = No)</b>		
Attend/Work at School	0.80 ( 0.70- 0.99)*	4.25 (3.86-4.67)***
International Travel	1.80 ( 1.26- 2.41)**	0.70 (0.49-0.99)
Domestic Travel	1.00 ( 0.84- 1.15)	0.84 (0.74-0.94)*
Clinical Care Sought	1.70 ( 1.45- 2.09)***	1.13 (0.96-1.32)

Chills/Shivering	4.30 ( 3.81- 4.81)***	0.95 (0.84-1.08)
Headaches	2.10 ( 1.88- 2.37)***	0.79 (0.73-0.86)***
Cough	4.10 ( 3.66- 4.68)***	2.86 (2.63-3.12)***
Ear Pain/Discharge	1.90 ( 1.57- 2.28)***	1.44 (1.22-1.69)***
Runny/Stuffy Nose	2.10 ( 1.84- 2.33)***	6.35 (5.73-7.06)***
Sore Throat	1.70 ( 1.51- 1.89)***	2.29 (2.11-2.49)***
Muscle/Body Aches	2.70 ( 2.45- 3.06)***	0.71 (0.65-0.79)***
Fatigue	1.70 ( 1.53- 1.91)***	1.09 (1.00-1.18)
Fever	4.20 ( 3.73- 4.67)***	1.87 (1.70-2.06)***
Sweats	3.20 ( 2.85- 3.70)***	0.94 (0.82-1.08)
Diarrhea	0.90 ( 0.81- 1.10)	0.57 (0.50-0.65)***
Trouble Breathing	1.50 ( 1.25- 1.74)***	0.98 (0.85-1.13)
Nausea/Vomiting	1.30 ( 1.13- 1.54)**	0.87 (0.76-0.99)*
Rash	0.70 ( 0.42- 1.15)	1.01 (0.73-1.37)
Loss of Smell/Taste	5.30 ( 4.54- 6.26)***	1.93 (1.60-2.31)***
Eye Pain	2.70 ( 2.26- 3.28)***	0.91 (0.73-1.11)
>3 Symptoms	3.50 ( 3.07- 3.91)***	1.72 (1.58-1.87)***
<b>Test History</b>		
No Prior Positive (Ref)	1.0	
Prior Positive (>90days)	1.30 ( 0.83- 1.92)	
No Prior Test	0.70 ( 0.59- 0.74)***	
<b>Vaccination Status</b>		
Not Fully Vaccinated (Ref)	1.0	
Fully >6m	5.40 ( 4.42- 6.50)***	
Fully <6m	1.70 ( 1.40- 2.05)***	
Boosted	6.00 ( 5.02- 7.12)***	
<b>Time Period</b>		
Wild-type variant (Ref)	1.0	1.0
Pre-Omicron Variants	1.80 ( 1.55- 2.07)***	3.26 (2.99-3.56)***
Omicron Variants	11.70 (10.20- 13.37)***	1.41 (1.17-1.69)**
<b>SARS-CoV-2 Incidence Indicator</b>	2.70 ( 2.52- 2.81)***	
<b>Oxford Stringency Index</b>	0.90 ( 0.95- 0.95)***	
<b>Rhinovirus Incidence Indicator</b>		1.13 (1.12-1.14)***

**eTable 4 . Adjusted Odds Ratios for SARS-CoV-2 Test Positivity by Time Period for Variables With Significant Interactions With Time Period**


	Wild-type Variant Period	Pre-Omicron Variants Period aOR (95% CI) <sup>1</sup>	p-value <sup>2</sup>	Omicron Variants Period aOR (95%CI) <sup>1</sup>	p-value <sup>3</sup>
<12 years	1.57 (1.13-2.16)	0.76 (0.30-1.68)	0.005	1.20 (0.48-3.07)	0.33
South King Country	1.88 (1.47-2.39)	1.46 (0.79-2.64)	0.14	1.08 (0.61-1.93)	<0.001
Confirmed Contact	4.98 (4.01-6.35)	4.89 (2.71-8.94)	0.92	1.75 (0.97-3.25)	<0.001
Suspected Contact	1.50 (1.11-2.03)	0.88 (0.35-2.07)	0.07	0.83 (0.36-1.94)	0.03
Attend/work at school	0.74 (0.50-1.03)	0.35 (0.12-0.83)	0.01	0.85 (0.35-1.99)	0.56
Loss of smell/taste	4.25 (3.2-5.65)	5.08 (2.42-10.81)	0.18	1.03 (0.42-2.49)	<0.001
Sore throat	0.69 (0.55-0.85)	0.65 (0.36-1.18)	0.74	2.00 (1.13-3.68)	<0.001
Cough	2.36 (1.95-2.89)	1.71 (1.01-3.03)	0.07	4.04 (2.37-7.31)	0.004

<sup>1</sup> Confidence intervals calculated by non-parametric bootstrap (1000 replicates).


<sup>2</sup> P-value for interaction between variable and pre-Omicron variant period.

<sup>3</sup> P-value for interaction between variable and Omicron period.

**eFigure 7. Adjusted Odds Ratios for Rhinovirus Test Positivity for Each Time Period for Variables With Significant Interactions With Time Period**



**eFigure 8. Cross-Correlation Between Rhinovirus and SARS-CoV-2 Test Positivity in the SCAN Study**



## eReferences.

1. Public Health Seattle & King County. *Social & Economic Inequalities in COVID-19 Testing and Outcomes in King County Census Tracts*; 2021. [https://kingcounty.gov/depts/health/communicable-diseases/documents/C19/king-county-serial-technical-report.ashx](https://kingcounty.gov/depts/health/covid-19/data/~/media/depts/health/communicable-diseases/documents/C19/king-county-serial-technical-report.ashx)
2. Paredes MI, Lunn SM, Famulare M, et al. Associations Between Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants and Risk of Coronavirus Disease 2019 (COVID-19) Hospitalization Among Confirmed Cases in Washington State: A Retrospective Cohort Study. *Clin Infect Dis*. 2022;2. doi:10.1093/cid/ciac279
3. Thomas Hale, Noam Angrist, Rafael Goldszmidt, Beatriz Kira, Anna Petherick, Toby Phillips, Samuel Webster, Emily Cameron-Blake, Laura Hallas, Saptarshi Majumdar and HT. A global panel database of pandemic policies (Oxford COVID-19 Government Response Tracker). *Nat Hum Behav*. Published online 2021. doi:<https://www.nature.com/articles/s41562-021-01079-8>
4. Chung E, Chow EJ, Wilcox NC, et al. Comparison of Symptoms and RNA Levels in Children and Adults with SARS-CoV-2 Infection in the Community Setting. *JAMA Pediatr*. 2021;98109:1-10. doi:10.1001/jamapediatrics.2021.2025
5. Burstein R, Althouse BM, Adler A, et al. Interactions among 17 respiratory pathogens: a cross-sectional study using clinical and community surveillance data. *medRxiv*. Published online 2022. /pmc/articles/PMC8845514/%0A/pmc/articles/PMC8845514/?report=abstract%0A<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8845514/>
6. Kim AE, Brandstetter E, Wilcox N, et al. Evaluating specimen quality and results from a community-wide, home-based respiratory surveillance study. *J Clin Microbiol*. 2021;59(5). doi:10.1128/JCM.02934-20
7. Jerome Friedman, Trevor Hastie RT. Regularization Paths for Generalized Linear Models via Coordinate Descent. *J Stat Softw*. 2010;33(1):1-22. <https://www.jstatsoft.org/v33/i01/>.
8. Adrian Raftery, Jennifer Hoeting, Chris Volinsky IP and KYY. BMA: Bayesian Model Averaging. R package version 3.18.17. Published online 2022. [https://cran.r-project.org/package=BMA%0A](https://cran.r-project.org/package=BMA)